Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting…
Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting…
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten…
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten…
Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC…
Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC…
SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc….
SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc….
International certification adds to Quality Management Systems credentials for the medical device industry and supports…
International certification adds to Quality Management Systems credentials for the medical device industry and supports…
$3 million awarded by DoD to University of North Carolina Institute of Trauma Recovery to…
$3 million awarded by DoD to University of North Carolina Institute of Trauma Recovery to…
– Everads’ next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which…
– Everads’ next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which…
Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1…
Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1…
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented…
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented…
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94%…
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94%…
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024…